Abstract Background Programmed death 1 (PD-1) blockade has clinical benefit in
microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after …

6 Background: KEYNOTE-177 (NCT02563002) evaluated the antitumor activity of
pembrolizumab (pembro) vs chemotherapy±bevacizumab or cetuximab (chemo) as first-line …

PURPOSE KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of
pembrolizumab in previously treated, metastatic, microsatellite instability–high/mismatch …

3500 B ackground: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002)
study 1L pembrolizumab (pembro) versus chemotherapy (chemo) provided superior …

Background Pembrolizumab has shown improved progression-free survival versus
chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch …

The FDA approved pembrolizumab on June 29, 2020, for the treatment of patients with
unresectable or metastatic microsatellite instability-high (MSI-H) colorectal cancer with no …

LBA4 Background: KEYNOTE-177 (NCT02563002) is a phase 3, randomized open-label
study evaluating the efficacy and safety of pembrolizumab (pembro) versus standard of care …

Background Pembrolizumab demonstrated durable clinical benefit and manageable safety
in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch …

3514 Background: Pembrolizumab is approved for the treatment of adult and pediatric
patients (pts) with previously treated MSI-H cancer regardless of tumor type or site. This …

PURPOSE Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high
microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations that …